Skip to main content

Table 1 Study parameters

From: Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru

Survival projection Value Sensitivity range Source
Dialysis (probability C2D)
 Treatment effect (hazard ratio) 0.42 0.21–0.71 Bravo-Zúñiga et al. [8]
 Lambdaa 0.008 0.007–0.009 Estimated
 Gammaa 0.938 0.925–0.952 Estimated
Mortality (probability C2Dth)
 Treatment effect (hazard ratio) 1 0.88–1.13 Bravo-Zúñiga et al. [8]
 Lambdaa 0.043 0.034–0.053 Estimated
 Gammaa 1.143 1.098–1.193 Estimated
Mortality among dialysis patients (probability D2Dth) 0.05   Cieza-Zevallos et al. [14]
Annual costs (USD)b    Estimated (see Table 2)
 RHP cost of treatment 531 452–611  
 Standard of care cost of treatment 45 38–52  
 Dialysis treatment 13,459 11,440–15,478  
 RHP Initial investment (one-time) 30,412   
 RHP annual operational costs 4995   
Utility scores    Go et al. [16]
 CKD event-free 0.84 0.76–0.92  
 First time dialysis 0.65 0.59–0.72  
General
 Discount rate costs and outcomes (%) 3 0–5  
 Exchange rate (PEN per USD) 3.3   Central Reserve Bank of Peru [17]
 Projection length (cycles) 30   
 Cycle length (years) 1   
  1. RHP Renal Health Program; CKD chronic kidney disease; USD United States Dollars; PEN Peruvian Soles
  2. aValues rounded to the third decimal
  3. bAll costing data was rounded to the closest integer